

World Journal of *Ophthalmology*

World J Ophthalmol 2016 August 12; 6(3): 20-27





Editorial Board

2016-2019

The *World Journal of Ophthalmology* Editorial Board consists of 217 members representing a team of worldwide experts in ophthalmology. They are from 36 countries, Australia (7), Austria (1), Belgium (1), Brazil (4), Bulgaria (1), Canada (4), China (14), Czech Republic (1), Egypt (5), Finland (1), France (2), Germany (5), Greece (5), India (13), Iran (5), Israel (6), Italy (12), Japan (11), Kuwait (1), Lebanon (1), Mexico (2), Netherlands (3), Nigeria (2), Norway (1), Oman (1), Pakistan (2), Poland (2), Portugal (1), Saudi Arabia (5), Singapore (5), South Korea (6), Spain (9), Switzerland (1), Turkey (9), United Kingdom (11), and United States (57).

EDITOR-IN-CHIEF

Umit U Inan, *Afyonkarahisar*

GUEST EDITORIAL BOARD MEMBERS

Ying-Shan Chen, *Hsin-Chu*
Shwu-Jiuan Sheu, *Kaohsiung*
Yung-Feng Shih, *Taipei*
Jia-Kang Wang, *New Taipei*

MEMBERS OF THE EDITORIAL BOARD



Australia

Colin I Clement, *Sydney*
Sheila G Crewther, *Melbourne*
Beatrix Feigl, *Brisbane*
John J Males, *Sydney*
Konrad Pesudovs, *Bedford Park*
David V Pow, *Brisbane*
Robert Wilke, *Sydney*



Austria

Stefan Sacu, *Vienna*



Belgium

Erik L Mertens, *Antwerp*



Brazil

Joao B.F. Fortes, *Porto Alegre-RS*
Rodrigo P.C. Lira, *Recife*

Tiago S Prata, *Sao Paulo*
Givago S Souza, *Belém*



Bulgaria

Desislava N Koleva-Georgieva, *Plovdiv*



Canada

Subrata Chakrabarti, *London*
Helen Chan, *Toronto*
Ediriweera Desapriya, *Vancouver*
Alexandre N Odashiro, *Montreal*



China

Hao Cui, *Harbin*
Qian-Ying Gao, *Guangzhou*
Vishal Jhanji, *Hong Kong*
Dexter Yu-Lung Leung, *Hong Kong*
Wen-Sheng Li, *Wenzhou*
Xiao-Ming Li, *Changchun*
Shao-Min Peng, *Changsha*
Yu-Sheng Wang, *Xi'an*
Hong Yan, *Xi'an*
Alvin L Young, *Hong Kong*



Czech Republic

Jeetendra Eswaraka, *Carlsbad*



Egypt

Mohamed Hosny, *Cairo*
Ahmed MEM Kotb, *Cairo*

Tamer A Macky, *Cairo*
Ahmed Samir, *Zagazig*
Wael M.A Soliman, *Assiut*



France

Salomon Y Cohen, *Paris*
David Hicks, *Strasbourg*



Germany

Carsten H Meyer, *Bonn*
Alireza Mirshahi, *Mainz*
Gisbert Richard, *Hamburg*
Johannes Schwartzkopff, *Freiburg*
Andreas Stahl, *Freiburg*



Greece

Ilias Georgalas, *Athens*
Michael A Grentzelos, *Heraklion*
Vassilios P Kozobolis, *Alexandroupolis*
Ioannis Mavrikakis, *Athens*
Argyrios Tzamalidis, *Thessaloniki*



India

Tushar Agarwal, *New Delhi*
Zia Chaudhuri, *Delhi*
Sepehr Feizi, *Tehran*
Ritu M Gilhotra, *Jaipur*
Vinod Kumar, *Delhi*
Padmamalini Mahendradas, *Bengaluru*
Ramar Manikandan, *Karaikudi*
Gaurav Prakash, *Chennai*
Velpandian Thirumurthy, *New Delhi*

Murugesan Vanathi, *New Delhi*
Pradeep Venkatesh, *New Delhi*
Sharadini Vyas, *Indore*



Iran

Fedra Hajizadeh, *Tehran*
Ebrahim Mikaniki, *Babol*
Mehrddad Mohammadpour, *Tehran*
Mohammad T Rajabi, *South Kargar*
M Reza Razeghinejad, *Shiraz*



Israel

Irit Bahar, *Petach Tiqva*
Adiel Barak, *Tel Aviv*
Guy Kleinmann, *Rehovot*
Jaime Levy, *Beer-Sheva*
Anat Loewenstein, *Tel Aviv*
Naphtali Savion, *Tel Hashomer*



Italy

Solmaz Abdolrahimzadeh, *Rome*
Stefano Baldassi, *Florence*
Vanessa Barbaro, *Venice*
Claudio Campa, *Milano*
Gian C Demontis, *Pisa*
Giuseppe L Giudice, *Padova*
Marco Guzzo, *Milan*
Pierluigi Iacono, *Rome*
Antonio Leccisotti, *Siena*
Shigeki Machida, *Iwate*
Cosimo Mazzotta, *Siena*
Luigi Mosca, *Rome*



Japan

Atsushi Hayashi, *Toyama*
Akira Hirata, *Saga*
Hiroshi Kobayashi, *Shimonoseki*
Toshinobu Kubota, *Nagoya*
Tatsuya Mimura, *Tokyo*
Taiji Sakamoto, *Kagoshima*
Yoshihiko Usui, *Tokyo*
Tsutomu Yasukawa, *Nagoya*
Shigeo Yoshida, *Fukuoka*



Kuwait

Hanan El-Sayed Badr, *Kuwait*



Lebanon

Sharbel D Fahed, *Beirut*



Mexico

Federico Castro-Munozledo, *Mexico City*
Alejandro Navas, *Mexico City*



Netherlands

Carel B Hoyng, *Nijmegen*
Jeroen van Rooij, *Rotterdam*



Nigeria

Opeyemi O Komolafe, *Owo*
Caleb D Mpyet, *Jos*



Norway

Morten C Moe, *Oslo*



Oman

Mohamed AM Mahdy, *Bur Al-Rudah*



Pakistan

Sharif A Issa, *Gaza*
Raheel Qamar, *Islamabad*



Poland

Michal S Nowak, *Lodz*
Bartosz L Sikorski, *Bydgoszcz*



Portugal

Joaquim CN Murta, *Coimbra*



Saudi Arabia

Khaled K.S. Abu-Amero, *Riyadh*
Hind M Alkatan, *Riyadh*
Imtiaz A Chaudhry, *Riyadh*
Celia Chen, *Celia*



Singapore

Leonard Pek-Kiang Ang, *Singapore*
Gemmy Chui Ming Cheung, *Singapore*
Philip F Stanley, *Singapore*
Louis-MG Tong, *Singapore*



South Korea

Young Jae Hong, *Seoul*
Hakyoun Kim, *Seoul*
Jae Woong Koh, *Gwangju*
Sung Chul Lee, *Seoul*
Ki Ho Park, *Seoul*
Kyung Chul Yoon, *Gwangju*



Spain

Mercedes Hurtado-Sarrio, *Valencia*

Antonio G Martinez, *Ames*
Javier A.M. Moreno, *Valladolid*
Amparo Navea-Tejerina, *Valencia*
Julio Ortega-Usobiaga, *Bilbao*
Isabel Pinilla, *Zaragoza*
Jaime Tejedor, *Madrid*
Manuel Vidal-Sanz, *Murcia*
Vicente Zanon-Moreno, *Valencia*



Switzerland

David Goldblum, *Basel*



Turkey

Ipek Akman, *Istanbul*
Dilek D Altinors, *Ankara*
Gokhan I Gulkilik, *Istanbul*
Necip Kara, *Istanbul*
Peykan Turkcuoglu, *Malatya*
Mustafa Unal, *Antalya*
Fatime N Yalcindag, *Ankara*
Elvin H Yildiz, *Ankara*



United Kingdom

Ipek Akman, *Istanbul*
Dilek D Altinors, *Ankara*
Gokhan I Gulkilik, *Istanbul*
Necip Kara, *Istanbul*
Peykan Turkcuoglu, *Malatya*
Mustafa Unal, *Antalya*
Fatime N Yalcindag, *Ankara*
Elvin H Yildiz, *Ankara*



United States

Juan-Carlos Abad, *Colombia*
J Fernando Arevalo, *Baltimore*
John P Berdahl, *Sioux Falls*
John D Bullock, *Kettering*
David J Calkins, *Nashville*
Michelle C Callegan, *Oklahoma City*
Robert Jin-Hong Chang, *Champaign*
Yan Chen, *Nashville*
Shravan Chintala, *Rochester*
Pinakin G Davey, *Pomona*
Deepinder K Dhaliwal, *Pittsburgh*
Timothy Q Duong, *San Antonio*
Ella G Faktorovich, *San Francisco*
Alireza Ghaffariyeh, *Indianapolis*
Hai-Yan Gong, *Boston*
Ribhi Hazin, *Cambridge*
Kamran Hosseini, *Alameda*
Winston W-Y Kao, *Cincinnati*
Gennady Landa, *New York*
Marlyn P Langford, *Shreveport*
Yun-Zheng Le, *Oklahoma City*
Jimmy K Lee, *New Haven*
Roger W Li, *Berkeley*
Hai-Xia Liu, *Bloomington*
Edward E Manche, *Stanford*
Darlene Miller, *Miami*
Timothy G Murray, *Miami*
Jason Noble, *Boston*

Athanasios Papakostas, *Framingham*
John S Penn, *Nashville*
Suofu Qin, *Irvine*
Kota V Ramana, *Galveston*
Shantan Reddy, *New York*
Sanket U Shah, *Indianapolis*
Naj Sharif, *Fort Worth*
Deepak Shukla, *Chicago*

Glorge L Spachth, *Philadelphia*
Jason E Stahl, *Overland Park*
Michael W Stewart, *Jacksonville*
Stephen Tsang, *New York*
Andrew T Tsin, *San Antonio*
Jing-Sheng Tuo, *Bethesda*
Roxana Ursea, *Tucson*
Raul Velez-Montoya, *Aurora*

Guo-Yong Wang, *New Orleans*
Rong-Fang Wang, *New York*
Barbara Wirostko, *Park*
Sudhakar A Yakkanti, *Omaha*
Xin-cheng Yao, *Birmingham*
Terri L Young, *Durham*
Sarah X Zhang, *Oklahoma City*
Xin-Ping Zhao, *Houston*



ORIGINAL ARTICLE

Basic Study

- 20 Human ciliary muscle cell responses to kinins: Activation of ERK1/2 and pro-matrix metalloproteinases secretion

Sharif NA, Patil R, Li L, Husain S

ABOUT COVER

Editorial Board Member of *World Journal of Ophthalmology*, Antonio Leccisotti, MD, PhD, Professor, Department of Ophthalmology, Casa di Cura Rugani, 53100 Siena, Italy

AIM AND SCOPE

World Journal of Ophthalmology (*World J Ophthalmol*, *WJO*, online ISSN 2218-6239, DOI: 10.5318) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJO covers topics concerning optometry, ocular fundus diseases, cataract, glaucoma, keratopathy, ocular trauma, strabismus, and pediatric ocular diseases, blindness prevention, diagnostic imaging, evidence-based medicine, epidemiology and nursing. Priority publication will be given to articles concerning diagnosis and treatment of ophthalmological diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING

World Journal of Ophthalmology is currently no indexing/abstracting.

FLYLEAF

I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Xin Kong*
Proofing Editorial Office Director: *Xiu-Xia Song*

NAME OF JOURNAL

World Journal of Ophthalmology

ISSN

ISSN 2218-6239 (online)

LAUNCH DATE

December 30, 2011

FREQUENCY

Quarterly

EDITOR-IN-CHIEF

Umit Ubeyt Inan, MD, Professor, Department of Ophthalmology, Medical School, Afyon Kocatepe University, 03200 Afyonkarahisar, Turkey

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/2218-6239/editorialboard.htm>

EDITORIAL OFFICE

Xiu-Xia Song, Director
Fang-Fang Ji, Vice Director
World Journal of Ophthalmology
Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
8226 Regency Drive,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>
<http://www.wjgnet.com>

PUBLICATION DATE

August 12, 2016

COPYRIGHT

© 2016 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION

<http://www.wjgnet.com/esps/>



Basic Study

Human ciliary muscle cell responses to kinins: Activation of ERK1/2 and pro-matrix metalloproteinases secretion

Najam A Sharif, Rajkumar Patil, Linya Li, Shahid Husain

Najam A Sharif, Rajkumar Patil, Linya Li, Pharmaceutical Research, Alcon Research, Ltd. (A Novartis Company), Fort Worth, TX 76134, United States

Shahid Husain, Ophthalmology, Medical University of South Carolina, Charleston, SC 29425, United States

Author contributions: All authors contributed to this paper.

Institutional review board statement: Since this is a basic research *in vitro* study, there was no institutional board review needed.

Institutional animal care and use committee statement: Since these were *in vitro* studies, no animals were involved, and thus no IACUC approval was necessary.

Conflict-of-interest statement: None of the authors have any conflict of interest or financial interest to report.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at naji333sha@yahoo.com. Participants gave informed consent for data sharing by signing copyright assignment form.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Najam A Sharif, PhD, Pharmaceutical Research, Alcon Research, Ltd. (A Novartis Company), 6201 South Freeway, Fort Worth, TX 76134, United States. naji333sha@yahoo.com
Telephone: +1-817-5657686
Fax: +1-415-2689181

Received: May 26, 2016

Peer-review started: May 26, 2016

First decision: July 5, 2016

Revised: July 29, 2016

Accepted: August 7, 2016

Article in press: August 8, 2016

Published online: August 12, 2016

Abstract

AIM

To study activation of extracellular signal-regulated kinase-1/2 (ERK1/2) and pro-matrix metalloproteinases (pro-MMPs) secretion from isolated primary human ciliary muscle (h-CM) cells in response to bradykinin (BK) and other agonists.

METHODS

Serum-starved h-CM cells were challenged with vehicle, BK agonists or antagonists. Cell lysates were evaluated for phosphorylated ERK1/2 using homogeneous time-resolved fluorescence technology based on a sandwich immunoassay. Rabbit polyclonal anti-pro-MMP antibodies were used to measure pro-MMPs using immunoblot analysis.

RESULTS

A 10 min incubation time using 5×10^4 h-CM cells/well was optimum condition for studying stimulation of ERK1/2 phosphorylation. BK (100 nmol/L) caused a 1.86 ± 0.26 fold ($n = 3$) increase in ERK1/2 phosphorylation above baseline. BK analogs, Met-Lys-BK and RMP-7 (100 nmol/L), also stimulated ERK1/2 phosphorylation by 1.57 ± 0.04 and 1.55 ± 0.09 fold, respectively. However, Des-Arg⁹-Bradykinin, a B₁ receptor-selective agonist (0.1-1 μ mol/L), was essentially inactive. HOE-140 or WIN-64338 (B₂-antagonists) appreciably blocked phosphorylation of ERK1/2 induced by various BK agonists. Pre-treatment

of cells with a prostaglandin (PG) synthase inhibitor (bromfenac; 1 μ mol/L) failed to alter kinin-induced ERK1/2 activation. BK and a non-peptide BK agonist (FR-190997) (10 nmol/L-1 μ mol/L) also enhanced pro-MMPs secretion (pro-MMP-1 > pro-MMP-3 > pro-MMP-2; 1.45-1.75-fold over baseline) from h-CM cells.

CONCLUSION

These collective data suggest that B₂ kinin receptors initiate signaling in h-CM cells by a relatively rapid mechanism (within minutes) involving ERK1/2 activation which in turn regulates MMPs production (within hours). The latter process does not involve PGs.

Key words: Extracellular signal-regulated kinase-1/2; Bradykinin; Ciliary muscle; Matrix metalloproteinases; B₂-receptor

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Bradykinin (BK), its peptide and non-peptide analogs and mimetic were potently and efficaciously able to stimulate extracellular signal-regulated kinase 1/2 phosphorylation in human ciliary muscle (h-CM) cells *in vitro*. Additionally, these agonists also induced the production and secretion of pro-matrix metalloproteinases in a prostaglandin-independent manner. Selective antagonists helped link these responses to be mediated *via* the B₂-receptor sub-type in h-CM cells. These mechanistic studies show how BK can lower intraocular pressure in animals when delivered to the eye.

Sharif NA, Patil R, Li L, Husain S. Human ciliary muscle cell responses to kinins: Activation of ERK1/2 and pro-matrix metalloproteinases secretion. *World J Ophthalmol* 2016; 6(3): 20-27 Available from: URL: <http://www.wjgnet.com/2218-6239/full/v6/i3/20.htm> DOI: <http://dx.doi.org/10.5318/wjo.v6.i3.20>

INTRODUCTION

Bradykinin (BK) and Lys-BK are generated from precursor polypeptides (kininogens) by the proteolytic actions of the enzymes kallikreins^[1,2]. BK, its synthetic components and constituents, and its signal-transducing receptor proteins (B₁- and B₂-receptors) are all present in the mammalian eye, including in the ciliary muscle, ciliary epithelium, trabecular meshwork, and the retina^[3-7]. Whilst there has been confusion about the physiological and pathological roles of BK in ocular function, in particular related to elevation or reduction of intraocular pressure (IOP)^[8-15], recent studies have clearly demonstrated that BK has some beneficial effects in the anterior chamber. Thus, BK and two non-peptide mimics of BK (FR-190997 and BKA278), cause IOP lowering in rabbits, mice and Cynomolgus monkeys when delivered intravitreally and/or topical ocularly^[16-18].

Additionally, BK and FR-190997 cause the IOP reduction by increasing uveoscleral outflow in living monkey eyes^[17] and by conventional outflow in isolated perfused bovine eye anterior chambers^[16-19].

The cellular and molecular pathways activated by BK B₂-receptors involve phosphoinositide hydrolysis, intracellular Ca²⁺-mobilization, and prostaglandin (PG) release^[16-19]. However, the elements linking these signal transduction pathways in the Human ciliary smooth muscle (h-CM) cells to IOP reduction have not been reported to our knowledge. Therefore, we embarked on the current studies in order to investigate the possible stimulation of extracellular signal-regulated kinase 1/2 (ERK1/2) and pro-MMPs secretion from isolated h-CM cells in response to BK and FR-190997. We utilized a number of BK-related peptides, a non-peptide BK agonist, two receptor-specific antagonists (Figure 1) to delineate the receptor-subtype mediating some of the actions of BK in h-CM cells in these mechanistic studies. In addition, we used a PG synthase inhibitor [bromfenac (BF); cyclooxygenase inhibitor; Figure 1] in order to determine whether PGs were involved in mediating the effects of BK agonists on ERK1/2 activation. A preliminary account of these studies was presented at a meeting of Association for Research in Vision and Ophthalmology (ARVO)^[20].

MATERIALS AND METHODS

Cell isolation and culture

h-CM cells were prepared from normal human cadaveric eyes using the procedure previously described earlier^[21-23]. In brief, human eyes were obtained from NDRI (Philadelphia, PA). Ciliary muscles were dissected with the aid of a dissecting microscope under sterile conditions, cleaned, and cut into 1-2 mm pieces. The explants were placed in DMEM containing 2 mg/mL collagenase type I A, 10% fetal bovine serum (FBS), and 50 μ g/mL gentamicin and then incubated for 1-2 h at 37 °C with occasional shaking. When a major part of the explant was dispersed into single cells or groups of cells, the cell suspension was centrifuged at 200 g for 10 min and re-suspended in DMEM supplemented with 10% FBS, 100 U/mL penicillin G, 100 μ g/mL streptomycin, and 0.25 μ g/mL amphotericin B and maintained in a 5% CO₂ humidified atmosphere. The confluent cells were sub-cultured at a split ratio of 1:4 using 0.05% trypsin and 0.02% EDTA. Cells of passage number 2-8 were used in the current studies obtained from numerous human donor eyes.

Immunoassay for ERK1/2

h-CM cells were initially seeded at different densities ranging from 1 \times 10⁴ to 1 \times 10⁵ and grown over 2 d in 96-well plates to 80%-90% confluence. Using cells at this confluence level prevented any potential contact inhibition, and thus the responses to pharmacological agents were not confounded by the latter factor. Once




Figure 1 Structures of compounds used in the current studies. BK: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg; Met-Lys-BK: Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg; RMP-7: H-Arg-Pro-Hyp-Gly-Thi-Ser-Pro-4-Me-Tyr ψ (CH $_2$ NH)-Arg-OH; Des-Arg⁹-BK: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe. A: FR-190997. HOE-140: H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (peptide B₂-receptor antagonist); D: D configuration of amino acid; D-BT: (3S)[amino]-5-(carbonylmethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; Hyp: Trans-4-Hydroxy-L-proline; Igl: α -(2-Indanyl)glycine; Oic: Octahydroindole-2-carboxylic acid; Thi: O-(2-thienyl)-alanine; Tic: L-1,2,3,4-Tetrahydroisoquinoline-3-carbonyl; TFA: Trifluoroacetic acid; B: WIN-64338 (non-peptide B₂-receptor antagonist); C: Bromfenac sodium (cyclooxygenase inhibitor; prostaglandin synthase inhibitor).

the optimum number of cells/well was determined, all subsequent experiments utilized 5×10^4 cells/well. Cells were then starved off serum overnight before being challenged with BK agonists or antagonists (Figure 1) for various times and with different ligands at various concentrations. Cells were lysed using lysis buffer provided in the Cellul'erk kit from CisBio (Bedford, MA) for direct detection of phosphorylated ERK1/2 at room temperature with shaking for 30 min after the ligand treatment. The cell lysates then received homogeneous time-resolved fluorescence (HTRF) conjugates containing phospho-ERK1/2 antibodies and the incubation continued for 2 additional hours at 23 °C. Phosphorylated ERK1/2 was then detected using an anti-phospho-ERK1/2 antibody labeled with d2 and an anti-ERK1/2 antibody labeled with Eu³⁺-Cryptate using HTRF technology based on a sandwich immunoassay. Recording of the fluorescence signals was performed at 620 nm for the donor and 665 nm for the acceptor^[20]. A 10-min incubation with agonist ligands using 5×10^4 cells was found to be optimum for such studies. B₂-receptor antagonists (HOE-140; WIN-64338) or an enzyme inhibitor (BF; PG synthase inhibitor) (Figure 1), when used, were added to the cells 15 min prior to the agonist compound.

Pro-MMP secretion from h-CM cells

For these experiments, 12 h-serum-starved (almost confluent) h-CM cells were incubated with the test compound or buffer vehicle for 6 h. This time-point

was chosen based on the peak IOP-reduction observed following intravitreal injection of BK^[16]. Centricon concentrators (10-kDa cutoff; Centricon-10; Amicon Beverly, MA) were then used to concentrate the incubation medium (10-fold) from each well and adjusted to a 10:1 concentration. The concentrated incubation media (40 μ L) were then loaded on SDS-polyacrylamide (10%) gels. This was followed thereafter by transfer to nitrocellulose membranes. The latter were first blocked with non-fat dry milk (5%) (Biorad, Hercules, CA), and then incubated with specific antibodies for pro-MMP-1 (Dilution at 1:1000; Cat# AV42039; Sigma-Aldrich, St. Louis, MO), pro-MMP-2 (Dilution at 1:1000; Cat# 1M-33, Calbiochem, Billerica, MA), or pro-MMP-3 (Dilution at 1:1000; Cat# Ab2963; Millipore, Billerica, MA) (12 h with gentle shaking at 4 °C). Synthetic peptides directed towards N-termini of human pro-MMP-1, pro-MMP-2, or pro-MMP-3 were used by the manufacturers to generate all the antibodies for pro-MMPs. Appropriate secondary antibodies (HRP-conjugated; dilution 1:3000) were incubated with the membranes for 1 h at 20 °C. Standard molecular-weight markers and pre-stained proteins were used in the same experiments for comparisons. At the appropriate time, these membranes were treated with enhanced chemiluminescent reagent (Amersham Pharmacia, Piscataway, NJ) and a Biorad Versadoc imaging system (Biorad, Hercules, CA) utilized to monitor the chemiluminescent signal^[21,22]. After this, quantitative densitometry was used to quantify the band intensities followed by normalization with cellular protein for each respective band. This process was followed to




Figure 2 Time-course of bradykinin activation of extracellular signal-regulated kinase-1/2 in cultured primary human ciliary muscle cells. Serum-deprived h-CM cells were incubated with either vehicle as control or with BK (100 nmol/L) for different time periods. At the end of incubation, cell lysates were analyzed for phosphorylated ERK1/2 as described in the Methods section. Data shown are blank (with nothing added), negative control (just vehicle added), followed by time control and with BK over 2-15 min. The BK-stimulated response was compared with its respective vehicle control at the same time of study. Statistical significances were determined by Student's *t*-test with $P < 0.05$ being the minimally acceptable level of significance. Data are mean \pm SEMs from 3 experiments. Differs from control at $^aP < 0.05$ by Student's *t*-test. The inset depicts a concentration-response curve for ERK1/2 activation by different concentrations of BK (1, 3, 10, 30, 100 nmol/L, etc.). ERK1/2: Extracellular signal-regulated kinase-1/2; h-CM: Human ciliary muscle; BK: Bradykinin.




Figure 3 Effect of B₂ and B₁ selective agonists on extracellular signal-regulated kinase-1/2 activation in cultured primary human ciliary muscle cells. Serum-deprived h-CM cells were incubated for 10 min with 100 nmol/L B₂ selective agonists (BK, Met-Lys-BK and RMP-7) or B₁ selective agonist (Des-Arg⁹-BK). At the end of incubation, cell lysates were analyzed for phosphorylated ERK1/2 using Cellul'erk kit from CisBio. Differs from base-line control, $^aP < 0.05$ by Student's *t*-test. ERK1/2: Extracellular signal-regulated kinase-1/2; h-CM: Human ciliary muscle; BK: Bradykinin.

differences between all treatments, with $P < 0.05$ being the minimally acceptable level of statistical significance.

RESULTS

Initial studies focused on determining the optimal conditions of ERK1/2 phosphorylation in primary h-CM cells. In response to BK (100 nmol/L), h-CM ERK1/2 phosphorylation was induced in a time (2-15 min)-dependent manner, being highest at 10-15 min relative to the basal levels (Figure 2). All subsequent experiments utilized 5×10^4 cells/well and a 10 min incubation with the agonist compound. When antagonists or an enzyme inhibitor were tested, they were added to the cells 15 min prior to agonist exposure.

BK concentration-dependently stimulated ERK1/2 phosphorylation in h-CM cells with a minimum at 3 nmol/L and a maximum at 1 μ mol/L (Figure 2 inset). Such concentration-response studied yielded half-maximal responses (EC_{50}^s ; efficacy) at 20 nmol/L and 80 nmol/L, from two independent experiments. While 100 nmol/L of the B₂-receptor agonists, BK, Met-Lys-BK, and RMP-7 (a metabolically stable analog of BK) stimulated ERK1/2 phosphorylation to approximately the same degree (1.6-fold above basal), the B₁-agonist, Des-Arg⁹-BK (0.1-1 μ mol/L) was much weaker at stimulating ERK1/2 phosphorylation in the same experiments (Figure 3). In the presence of the B₂-receptor antagonists, WIN-64338 and HOE-140 (both at 100 nmol/L), ERK1/2 phosphorylation was significantly reduced for the afore-mentioned B₂-agonists (Figure

account for potential differences in cell densities/well. Student's *t*-test was used to determine potential statistical




Figure 4 Extracellular signal-regulated kinase-1/2 activation in cultured primary human ciliary muscle cells. Effects of two B₂-receptor antagonists on kinin-induced ERK1/2 activation by three BK agonists are shown in (A). Effect of bromfenac on kinin-mediated ERK1/2 activation are shown in (B). Serum-deprived h-CM cells were incubated for 10 min with 100 nmol/L B₂ selective agonists BK, Met-Lys-BK and RMP-7. In experiments with antagonists or bromfenac, cells were pretreated with 100 nmol/L B₂ receptor antagonist HOE-140 or WIN-64338 or bromfenac (1 μmol/L) for 15 min prior to addition of BK agonists. At the end of incubation, cell lysates were analyzed for phosphorylated ERK1/2 using Cellul'erk kit from CisBio. Significantly different than basal responses, ^a*P* < 0.05 by Student's *t*-test. BK: Bradykinin; ERK1/2: Extracellular signal-regulated kinase-1/2; h-CM: Human ciliary muscle; BF: Bromfenac.

4A). However, pretreatment of h-CM cells with the PG synthase inhibitor BF (1 μmol/L) failed to effect the ERK1/2 phosphorylation induced by BK, Met-Lys-BK or RMP-7 (Figure 4B). BF by itself was also inactive (Figure 4B).

BK and FR-190997 (10 nmol/L-1 μmol/L) stimulated the production/secretion of pro-MMPs from h-CM cells but in a differential manner (pro-MMP-1 > pro-MMP-3 > pro-MMP-2) (Figure 5). However, while the FR-190997 and BK effects were similar on pro-MMP-3 and pro-MMP-2 secretion (Figure 5B and C), BK was a little less efficacious than FR-190997 at stimulating pro-MMP-1 (Figure 5A). However, these differences were statistically insignificant. In additional experiments, the latter agonists also enhanced pro-MMP-2 and -3 secretion (1.4-1.7-fold increase above baseline) from h-CM cells after 24 h incubation with the cells (data not shown). While a minor limitation of the current studies is that active forms of MMP-1-3 were not studied, previous work from our research has demonstrated a closely linked process of pro-MMP secretion and their conversion to the active species in human ocular cells^[19,21].

DISCUSSION

Under normal physiological conditions BK primarily activates B₂-receptors to mediate its biological effects in the mammalian body^[1,2]. Various tissues and cells of the mammalian eye also respond this way as shown using a variety of cell- and tissue-based assays and models^[4-7,16-20]. With respect to the actions of BK in h-CM cells, we have recently reported the existence

of B₂-receptor protein and its activation leading to generation of various intracellular second messengers such as inositol phosphates (IPs) and intracellular Ca²⁺ whose elevation then causes the release of various PGs (mainly PGE₂ and PGF_{2α})^[16-18]. In the current studies in h-CM cells we have extended those observations by demonstrating the relatively fast phosphorylation of ERK1/2 in response to BK and its close analogs, Met-Lys-BK and the stabilized BK-mimetic RMP-7. Consistent with only the stimulation of the B₂-receptor, it was evident that the B₁-receptor agonist Des-Arg⁹-BK lacked activity in this regard, and indeed two B₂-receptor-selective antagonists, HOE-140 and WIN-64338, blocked the effects of BK on ERK1/2 phosphorylation. Since a PG synthase inhibitor, BF, failed to reduce BK, Met-Lys-BK and RMP-7-induced ERK1/2 activation in h-CM cells, it appears that ERK1/2 phosphorylation occurs directly and is not mediated indirectly by PGs, at least within the first 10 min of receptor activation *in vitro*. Further down-stream from B₂-receptor activation by BK or a non-peptide BK mimetic agonist, FR-190997, is for instance the generation of pro-MMPs from h-CM cells. This is a time-dependent process that apparently requires several hours. Accordingly, both BK and FR-190997 up-regulated the production of pro-MMP-1-3 in h-CM cells to a similar extent after the agonists were incubated with h-CM cells. BK has also been shown to stimulate ERK1/2 phosphorylation in isolated human trabecular meshwork (h-TM) cells followed by release of MMP-9^[24]. Thus, similar series of events ensue following B₂-receptor activation by BK in h-CM and h-TM cells. A unifying signal transduction pathway applicable to the h-CM and h-TM cell responses to kinins appears to be




Figure 5 Effect of Bradykinin and FR-190997 on pro-matrix metalloproteinases generation in human ciliary muscle cells. The levels of pro-MMPs produced by h-CM cells following exposure to different concentrations of either BK or FR-190997 for 6 h were determined as described in the methods section. Results shown are mean \pm SEM from $n = 8$ for pro-MMP-1 (A); $n = 6-8$ for pro-MMP-2 (B); $n = 4-8$ for pro-MMP-3 (C). ^a $P < 0.05$; ^b $P < 0.01$ relative to base-line controls by Student's *t*-test. BK: Bradykinin; h-CM: Human ciliary muscle; pro-MMPs: Pro-matrix metalloproteinases.

as follows: BK, or its stabilized-mimetic (RMP-7) or a synthetic non-peptide analog (FR-190997), bind to the

B₂-receptor with high affinity that induces the G-protein (G_q) that couples to the receptor and activates

phospholipase C which then hydrolyzes membrane-bound phospholipids to liberate IP₃^[25] and diacyl glycerol (DAG) into the cellular cytoplasm. IP₃ then liberate intracellular Ca²⁺ from the endoplasmic reticulum^[15-18] while DAG activates protein kinase C which then activates ERK1/2 *via* phosphorylation by a mitogen-activated protein kinase^[21]. These events are followed by specific induction and release of pro-MMPs into the extracellular space where they are activated. Digestion of extracellular matrix by MMPs^[26] leads to the creation of several gaps between bundles of ciliary muscle and scleral tissues, and perhaps within the TM, to promote outflow of aqueous humor that then causes reduction in the IOP^[17-19]. Accordingly, FR-190997 perfused into bovine anterior segments increased outflow of fluid, starting within an hour and reaching an apparent plateau around 4 h of perfusion^[17]. It is interesting to note that similar findings were also reported for BK when it was perfused in the same model^[19]. In a correlative manner, intravitreally delivered BK in Dutch-belt rabbits has been demonstrated to lower IOP starting around 4-6 h after injection and peaking at 8 h post-injection^[16]. Both these events require several hours to be fully operational thereby correlating with the time-course of pro-MMPs production/secretion induced by BK and FR-190997 from h-CM cells (our current study; and from h-TM cells^[24]), and stimulation of outflow of fluid in the perfused anterior eye segment model mentioned above^[17-19].

These collective data provide further evidence for the involvement of B₂-receptors in h-CM cells mediating ERK1/2 activation and pro-MMP-1-3 secretion in response to BK and other B₂-receptor agonists. This information correlates well with the time-course of activity of intravitreally injected BK causing IOP-reduction in rabbits^[16], without the involvement of B₁-receptors^[17-19,24].

COMMENTS

Background

Prior studies in human ciliary muscle (h-CM) cells revealed that activation of bradykinin (BK) B₂-receptors results in generation of two second messengers (inositol phosphates, Ca²⁺) that then cause prostaglandin E₂ and other prostaglandins (PGs) secretion. The net result of such events *in vivo*, for instance when BK is injected into the posterior eye segment of rabbits, is the stimulation of aqueous humor outflow from the front of the eye to cause a reduction in intraocular pressure (IOP). However, The authors envisaged that there may be other key biochemical steps involved after B₂-receptors activation in h-CM cells, and thus embarked on unravelling these potential pathways.

Research frontiers

The authors discovered that indeed, BK and its close peptide and non-peptide analogs/mimetic, stimulate extracellular signal-regulated kinase 1/2 (ERK1/2) and promote secretion of pro-matrix metalloproteinases (pro-MMPs) from isolated h-CM cells. The B₂-receptor involvement in these responses was confirmed utilizing two selective receptor antagonists. The authors also showed that PGs were not involved in such processes since a PG-synthase inhibitor did not influence those responses to BK.

Innovations and breakthroughs

The innovative portion of the studies involved utilizing classical pharmacological

tools coupled with modern cellular and molecular biochemistry to delineate the early-stage and late-phase actions of BK in h-CM cells *in vitro*. These studies may help explain the time-course of activity of this endogenous peptide in causing and controlling IOP reduction *in vivo* when it is delivered to the inside of the eye.

Applications

It is hoped that other researchers would be encouraged and excited by the use of such multidisciplinary techniques, tools and technologies, and the overall results, to undertake additional mechanistic studies. Additional exploration of similar mechanisms in other ocular cells involved in aqueous humor dynamics, including non-pigmented ciliary epithelial cells, scleral fibroblasts and other scleral tissue-derived cells, and Schlemm's canal cells would be very informative.

Terminology

Since some readers may not be so familiar with various terms and abbreviations used in the current paper, a list of the most commonly used terms is provided below. IOP is controlled by the rate of aqueous humor (AQH) formation by the ciliary processes and its drainage from the anterior chamber of the eye. Since IOP is a major risk factor for glaucoma, it is important to learn what and how it can be modulated to help preserve vision. AQH: Aqueous humor; BK: Bradykinin; EC₅₀: Concentration of agonist that produces half-maximal response; ERK1/2: Extracellular signal-regulated kinase-1/2; h-CM: Human ciliary muscle; IOP: Intraocular pressure; PG: Prostaglandin; pro-MMPs: Pro-matrix metalloproteinases.

Peer-review

The manuscript is a mechanistic study describing the molecular sequences by which activated bradykinin receptors initiate a rapid signalling cascade through ERK1/2 which in turn activate the MMP-1, -2 and -3 production leading to subsequent events (previously published by the authors). The topic of study is good.

REFERENCES

- 1 **Bhoola KD**, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. *Pharmacol Rev* 1992; **44**: 1-80 [PMID: 1313585]
- 2 **Leeb-Lundberg LM**, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. *Pharmacol Rev* 2005; **57**: 27-77 [PMID: 15734727 DOI: 10.1124/pr.57.1.2]
- 3 **Igić R**. Kallikrein and kininases in ocular tissues. *Exp Eye Res* 1985; **41**: 117-120 [PMID: 2993009 DOI: 10.1016/0014-4835(85)90100-9]
- 4 **Ma JX**, Song Q, Hatcher HC, Crouch RK, Chao L, Chao J. Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. *Exp Eye Res* 1996; **63**: 19-26 [PMID: 8983960 DOI: 10.1006/exer.1996.0087]
- 5 **Crook RB**, Polansky JR. Neurotransmitters and neuropeptides stimulate inositol phosphates and intracellular calcium in cultured human nonpigmented ciliary epithelium. *Invest Ophthalmol Vis Sci* 1992; **33**: 1706-1716 [PMID: 1348499]
- 6 **Wiernas TK**, Davis TL, Griffin BW, Sharif NA. Effects of bradykinin on signal transduction, cell proliferation, and cytokine, prostaglandin E₂ and collagenase-1 release from human corneal epithelial cells. *Br J Pharmacol* 1998; **123**: 1127-1137 [PMID: 9559896 DOI: 10.1038/sj.bjp.0701700]
- 7 **Webb JG**, Yang X, Crosson CE. Expression of the kallikrein/kinin system in human anterior segment. *Exp Eye Res* 2009; **89**: 126-132 [PMID: 19268469 DOI: 10.1016/j.exer.2009.02.016]
- 8 **Zeller EA**, Shoch D, Czermer TB, Hsu MY, Knepper PA. Enzymology of the refractory media of the eye. X. Effects of topically administered bradykinin, amine releasers, and pargyline on aqueous humor dynamics. *Invest Ophthalmol* 1971; **10**: 274-281 [PMID: 5549592]

- 9 **Chiang TS.** Effects of intravenous infusions of histamine 5-hydroxytryptamine, bradykinin and prostaglandins on intraocular pressure. *Arch Int Pharmacodyn Ther* 1974; **207**: 131-138 [PMID: 4824887]
- 10 **Cole DF,** Unger WG. Action of bradykinin on intraocular pressure and papillary diameter. *Ophthalmol Res* 1974; **6**: 308-314 [DOI: 10.1159/000264717]
- 11 **Green K,** Elijah D. Drug effects on aqueous humor formation and pseudofacility in normal rabbit eyes. *Exp Eye Res* 1981; **33**: 239-245 [PMID: 7286083 DOI: 10.1016/S0014-4835(81)80047-4]
- 12 **Kaufman PL,** Bárány EH, Erickson KA. Effect of serotonin, histamine and bradykinin on outflow facility following ciliary muscle retrodisplacement in the cynomolgus monkey. *Exp Eye Res* 1982; **35**: 191-199 [PMID: 7151886 DOI: 10.1016/S0014-4835(82)80066-3]
- 13 **Bynke G,** Håkanson R, Hørig J, Leander S. Bradykinin contracts the pupillary sphincter and evokes ocular inflammation through release of neuronal substance P. *Eur J Pharmacol* 1983; **91**: 469-475 [PMID: 6193973 DOI: 10.1016/0014-2999(83)90172-3]
- 14 **Yokoyama K,** Awaya S, Mizumura K, Kumazawa T. Implication of polymodal receptor activities in intraocular pressure elevation by neurogenic inflammation. *Jpn J Ophthalmol* 1990; **34**: 245-255 [PMID: 1699016]
- 15 **Llobet A,** Gual A, Palés J, Barraquer R, Tobías E, Nicolás JM. Bradykinin decreases outflow facility in perfused anterior segments and induces shape changes in passaged BTM cells in vitro. *Invest Ophthalmol Vis Sci* 1999; **40**: 113-125 [PMID: 9888434]
- 16 **Sharif NA,** Xu S, Li L, Katoli P, Kelly CR, Wang Y, Cao S, Patil R, Husain S, Klekar L, Scott D. Protein expression, biochemical pharmacology of signal transduction, and relation to intraocular pressure modulation by bradykinin B2 receptors in ciliary muscle. *Mol Vis* 2013; **19**: 1356-1370 [PMID: 23805043]
- 17 **Sharif NA,** Katoli P, Scott D, Li L, Kelly C, Xu S, Husain S, Toris C, Crosson C. FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys. *Drug Dev Res* 2014; **75**: 211-223 [PMID: 24796320 DOI: 10.1002/ddr.21174]
- 18 **Sharif NA,** Li L, Katoli P, Xu S, Veltman J, Li B, Scott D, Wax M, Gallar J, Acosta C, Belmonte C. Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule. *Exp Eye Res* 2014; **128**: 170-180 [PMID: 25307520 DOI: 10.1016/j.exer.2014.10.008]
- 19 **Webb JG,** Husain S, Yates PW, Crosson CE. Kinin modulation of conventional outflow facility in the bovine eye. *J Ocul Pharmacol Ther* 2006; **22**: 310-316 [PMID: 17076624 DOI: 10.1089/jop.2006.22.310]
- 20 **Patil R,** Li L, Sharif NA. Activation of ERK signaling pathway by bradykinin B2-receptors in isolated human primary ciliary muscle cells. *Invest Ophthalmol Vis Sci* 2012: ARVO Abst. # 1971
- 21 **Husain S,** Jafri F, Crosson CE. Acute effects of PGF2alpha on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process. *Invest Ophthalmol Vis Sci* 2005; **46**: 1706-1713 [PMID: 15851572 DOI: 10.1167/iops.04-0993]
- 22 **Sharif NA,** McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. *Exp Eye Res* 2009; **88**: 386-397 [PMID: 18992242 DOI: 10.1016/j.exer.2008.10.003]
- 23 **Sharif NA,** Kelly CR, Crider JY, Davis TL. Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. *J Ocul Pharmacol Ther* 2006; **22**: 389-401 [PMID: 17238805 DOI: 10.1089/jop.2006.22.389]
- 24 **Webb JG,** Yang X, Crosson CE. Bradykinin activation of extra-cellular signal-regulated kinases in human trabecular meshwork cells. *Exp Eye Res* 2011; **92**: 495-501 [PMID: 21426904 DOI: 10.1016/j.exer.2011.03.009]
- 25 **Sharif NA,** Xu SX. Pharmacological characterization of bradykinin receptors coupled to phosphoinositide turnover in SV40-immortalized human trabecular meshwork cells. *Exp Eye Res* 1996; **63**: 631-637 [PMID: 9068370 DOI: 10.1006/exer.1996.0157]
- 26 **Weinreb RN,** Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. *Invest Ophthalmol Vis Sci* 1997; **38**: 2772-2780 [PMID: 9418730]

P- Reviewer: Felix K, Fang Y, Soriano-Ursua MA **S- Editor:** Ji FF
L- Editor: A **E- Editor:** Lu YJ





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

